Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in
Japanese patients with T2DM at first treatment period. The second treatment period is
required to obtain sufficient safety data (one-year exposure to BI 10773) in Japanese
patients with T2DM according to the ICH E1 guideline.